Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration

neurodegeneration resolved
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
—
Novelty
—
Mechanistic
—
Druggability
—
Priority
85%
Importance
—
Tractability
—
Market price
50%

Description

How can DNA methylation clocks, histone modification patterns, and epigenetic age acceleration serve as biomarkers for Alzheimer disease, Parkinson disease, and related neurodegenerative conditions?

Focus areas:

  1. Diagnostic biomarker utility: Can epigenetic clocks distinguish AD from other dementias? What is the sensitivity/specificity?
  2. Prognostic value: Does epigenetic age acceleration correlate with disease progression, cognitive decline rate, or conversion from MCI to AD?
  3. Biomarker validation: What blood, CSF, or tissue samples are available for validation? Which clock algorithms (Horvath, Hannum, PhenoAge, GrimAge) perform best?
  4. Mechanistic links: How do epigenetic changes relate to tau pathology, amyloid burden, alpha-synuclein, TDP-43, and other neurodegenerative hallmarks?
  5. Confounding factors: How do comorbidities (vascular disease, diabetes), lifestyle, and cell type composition affect epigenetic biomarker readings?

The existing gap on therapeutic approaches (gap-v2-bc5f270e) addressed epigenetic clock modulation as therapy. This gap focuses specifically on biomarker development and validation for diagnosis, prognosis, and disease monitoring.